Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun 15:3:16015.
doi: 10.1038/mto.2016.15. eCollection 2016.

Clinical manufacturing of CAR T cells: foundation of a promising therapy

Xiuyan Wang  1 , Isabelle Rivière  1
Affiliations
Review

Clinical manufacturing of CAR T cells: foundation of a promising therapy

Xiuyan Wang et al. Mol Ther Oncolytics. .

Abstract

The treatment of cancer patients with autologous T cells expressing a chimeric antigen receptor (CAR) is one of the most promising adoptive cellular therapy approaches. Reproducible manufacturing of high-quality, clinical-grade CAR-T cell products is a prerequisite for the wide application of this technology. Product quality needs to be built-in within every step of the manufacturing process. We summarize herein the requirements and logistics to be considered, as well as the state of the art manufacturing platforms available. CAR-T cell therapy may be on the verge of becoming standard of care for a few clinical indications. Yet, many challenges pertaining to manufacturing standardization and product characterization remain to be overcome in order to achieve broad usage and eventual commercialization of this therapeutic modality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Major steps in chimeric antigen receptor-T-cell manufacturing process and examples of available technologies and devices. AAPC, artificial antigen-presenting cells; MPC, magnetic particle concentrator.
See this image and copyright information in PMC

References

    1. Yee, C (2014). The use of endogenous T cells for adoptive transfer. Immunol Rev 257: 250–263. - PubMed
    1. Sadelain, M, Brentjens, R and Rivière, I (2013). The basic principles of chimeric antigen receptor design. Cancer Discov 3: 388–398. - PMC - PubMed
    1. Brentjens, RJ, Davila, ML, Riviere, I, Park, J, Wang, X, Cowell, LG, et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra138. - PMC - PubMed
    1. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509–1518. - PMC - PubMed
    1. Davila, ML, Riviere, I, Wang, X, Bartido, S, Park, J, Curran, K, et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra225. - PMC - PubMed